{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:33:46Z","timestamp":1765370026889},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,23]]},"DOI":"10.7759\/cureus.24427","type":"journal-article","created":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T05:26:18Z","timestamp":1650777978000},"source":"Crossref","is-referenced-by-count":2,"title":["Safety and Effectiveness of Roxadustat in Dialysis-Dependent Patients With Renal Anemia: A Hospital-Based Cohort Study"],"prefix":"10.7759","author":[{"given":"Oumarou","family":"Moussa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian Xiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng Xia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian Hu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh J","year":"2007","unstructured":"Coresh J, Selvin E, Stevens LA, et al.. Prevalence of chronic kidney disease in the United States. JAMA. 2007, 298:2038-47. 10.1001\/jama.298.17.2038","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60033-6","article-title":"Prevalence of chronic kidney disease in China: a cross-sectional survey","volume":"3","author":"Zhang L","year":"2012","unstructured":"Zhang L, Wang F, Wang L, et al.. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012, 3:815-22. 10.1016\/S0140-6736(12)60033-6","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(98)70176-3","article-title":"Trends in anemia treatment with erythropoietin usage and patient outcomes","volume":"4","author":"Collins AJ","year":"1998","unstructured":"Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis. 1998, 4:133-41. 10.1016\/s0272-6386(98)70176-3","journal-title":"Am J Kidney Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement","volume":"28","author":"Locatelli F","year":"2013","unstructured":"Locatelli F, B\u00e1r\u00e1ny P, Covic A, et al.. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013, 28:1346-59. 10.1093\/ndt\/gft033","journal-title":"Nephrol Dial Transplant"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.03.011","article-title":"II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults","volume":"47","author":"KDOQI; National Kidney Foundation","year":"2006","unstructured":"KDOQI; National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006, 47:S16-85. 10.1053\/j.ajkd.2006.03.011","journal-title":"Am J Kidney Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nephro.2014.02.005","article-title":"Therapy of anemia and iron deficiency in dialysis patients: an update [Article in French]","volume":"10","author":"Rostoker G","year":"2014","unstructured":"Rostoker G, Hummel A, Chantrel F, Ryckelynck JP. Therapy of anemia and iron deficiency in dialysis patients: an update [Article in French]. Nephrol Ther. 2014, 10:221-7. 10.1016\/j.nephro.2014.02.005","journal-title":"Nephrol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79531-4","article-title":"Baseline data report of the China Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"11","author":"Zhao X","year":"2021","unstructured":"Zhao X, Niu Q, Gan L, et al.. Baseline data report of the China Dialysis Outcomes and Practice Patterns Study (DOPPS). Sci Rep. 2021, 11:873. 10.1038\/s41598-020-79531-4","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2010.00836.x","article-title":"2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease","volume":"14","author":"Tsubakihara Y","year":"2010","unstructured":"Tsubakihara Y, Nishi S, Akiba T, et al.. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial. 2010, 14:240-75. 10.1111\/j.1744-9987.2010.00836.x","journal-title":"Ther Apher Dial"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2014.11.023","article-title":"Restless legs syndrome in pregnancy is connected with iron deficiency","volume":"16","author":"Min\u00e1r M","year":"2015","unstructured":"Min\u00e1r M, Ko\u0161utzk\u00e1 Z, Hab\u00e1nov\u00e1 H, Rus\u0148\u00e1k I, Planck K, Valkovi\u010d P. Restless legs syndrome in pregnancy is connected with iron deficiency. Sleep Med. 2015, 16:589-92. 10.1016\/j.sleep.2014.11.023","journal-title":"Sleep Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech LA","year":"2008","unstructured":"Szczech LA, Barnhart HX, Inrig JK, et al.. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008, 74:791-8. 10.1038\/ki.2008.295","journal-title":"Kidney Int"},{"key":"ref11","unstructured":"Fibrogen announces approval of roxadustat in China for the treatment of anemia in chronic kidney disease patients on dialysis. (2018). https.\/\/investor.fibrogen.com\/news-releases\/news-release-details\/fibrogen-announces-approval-roxadustat-china-treatme...."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12888","article-title":"Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study","volume":"24","author":"Akizawa T","year":"2020","unstructured":"Akizawa T, Otsuka T, Reusch M, Ueno M. Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study. Ther Apher Dial. 2020, 24:115-25. 10.1111\/1744-9987.12888","journal-title":"Ther Apher Dial"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: a\u00a0potential new treatment for anemia in patients with CKD","volume":"69","author":"Gupta N","year":"2017","unstructured":"Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a\u00a0potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017, 69:815-26. 10.1053\/j.ajkd.2016.12.011","journal-title":"Am J Kidney Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt JL","year":"2012","unstructured":"Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012, 23:1631-4. 10.1681\/ASN.2011111078","journal-title":"J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano R","year":"2016","unstructured":"Provenzano R, Besarab A, Wright S, et al.. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016, 67:912-24. 10.1053\/j.ajkd.2015.12.020","journal-title":"Am J Kidney Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen N","year":"2017","unstructured":"Chen N, Qian J, Chen J, et al.. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017, 32:1373-86. 10.1093\/ndt\/gfx011","journal-title":"Nephrol Dial Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase\u00a03, randomized, open-label, active-controlled study (PYRENEES)","volume":"38","author":"Csiky B","year":"2021","unstructured":"Csiky B, Sch\u00f6mig M, Esposito C, Barratt J, Reusch M, Valluri U, Sulowicz W. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase\u00a03, randomized, open-label, active-controlled study (PYRENEES). Adv Ther. 2021, 38:5361-80. 10.1007\/s12325-021-01904-6","journal-title":"Adv Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266243","article-title":"The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials","volume":"17","author":"Abdelazeem B","year":"2022","unstructured":"Abdelazeem B, Shehata J, Abbas KS, et al.. The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials. PLoS One. 2022, 17:e0266243. 10.1371\/journal.pone.0266243","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen N","year":"2019","unstructured":"Chen N, Hao C, Liu BC, et al.. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019, 381:1011-22. 10.1056\/NEJMoa1901713","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano R","year":"2021","unstructured":"Provenzano R, Shutov E, Eremeeva L, et al.. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant. 2021, 36:1717-30. 10.1093\/ndt\/gfab051","journal-title":"Nephrol Dial Transplant"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study","volume":"33","author":"Fishbane S","year":"2022","unstructured":"Fishbane S, Pollock CA, El-Shahawy M, et al.. Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study. J Am Soc Nephrol. 2022, 33:850-66. 10.1681\/ASN.2020111638","journal-title":"J Am Soc Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/BF01075997","article-title":"Changes in plasma lipids and lipoprotein cholesterol during a high altitude mountaineering expedition (4800 m)","volume":"57","author":"F\u00e9r\u00e9zou J","year":"1988","unstructured":"F\u00e9r\u00e9zou J, Richalet JP, Coste T, Rathat C. Changes in plasma lipids and lipoprotein cholesterol during a high altitude mountaineering expedition (4800 m). Eur J Appl Physiol Occup Physiol. 1988, 57:740-5. 10.1007\/BF01075997","journal-title":"Eur J Appl Physiol Occup Physiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9050468","article-title":"HIF-\u03b1 prolyl hydroxylase inhibitors and their implications for biomedicine: a comprehensive review","volume":"9","author":"Hirota K","year":"2021","unstructured":"Hirota K. HIF-\u03b1 prolyl hydroxylase inhibitors and their implications for biomedicine: a comprehensive review. Biomedicines. 2021, 9:468. 10.3390\/biomedicines9050468","journal-title":"Biomedicines"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.667117","article-title":"Effects of roxadustat on the anemia and iron metabolism of patients undergoing peritoneal dialysis","volume":"8","author":"Hirai K","year":"2021","unstructured":"Hirai K, Nonaka H, Ueda M, et al.. Effects of roxadustat on the anemia and iron metabolism of patients undergoing peritoneal dialysis. Front Med (Lausanne). 2021, 8:667117. 10.3389\/fmed.2021.667117","journal-title":"Front Med (Lausanne)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1993821","article-title":"An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease","volume":"23","author":"Kurata Y","year":"2022","unstructured":"Kurata Y, Tanaka T, Nangaku M. An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease. Expert Opin Pharmacother. 2022, 23:19-28. 10.1080\/14656566.2021.1993821","journal-title":"Expert Opin Pharmacother"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2020.12.001","article-title":"Anemia of cardiorenal syndrome","volume":"11","author":"McCullough PA","year":"2021","unstructured":"McCullough PA. Anemia of cardiorenal syndrome. Kidney Int Suppl. 2021, 11:35-45. 10.1016\/j.kisu.2020.12.001","journal-title":"Kidney Int Suppl"},{"key":"ref27","unstructured":"US Food & Drug Administration. Cardiovascular and Renal Drugs Advisory Committee. (2021). Accessed. July 15, 2021: https:\/\/www.fda.gov\/advisory-committees\/human-drug-advisory-committees\/cardiovascular-and-renal-drugs-advisory-committee."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.14744\/AnatolJCardiol.2018.08634","article-title":"Anemia in heart failure - from guidelines to controversies and challenges","volume":"20","author":"S\u00eerbu O","year":"2018","unstructured":"S\u00eerbu O, Floria M, Dascalita P, Stoica A, Adascalitei P, Sorodoc V, Sorodoc L. Anemia in heart failure - from guidelines to controversies and challenges. Anatol J Cardiol. 2018, 20:52-9. 10.14744\/AnatolJCardiol.2018.08634","journal-title":"Anatol J Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.03.025","article-title":"Effect of the phosphate binders Sevelamer carbonate and calcium acetate on the pharmacokinetics of roxadustat after concomitant or time-separated administration in healthy individuals","volume":"43","author":"Groenendaal-van de Meent D","year":"2021","unstructured":"Groenendaal-van de Meent D, Kerbusch V, Barroso-Fernandez B, den Adel M, van Dijk J, Golor G, Schaddelee M. Effect of the phosphate binders Sevelamer carbonate and calcium acetate on the pharmacokinetics of roxadustat after concomitant or time-separated administration in healthy individuals. Clin Ther. 2021, 43:1079-91. 10.1016\/j.clinthera.2021.03.025","journal-title":"Clin Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.05.025","article-title":"State-of-the-art management of hyperphosphatemia in patients with CKD: an NKF-KDOQI controversies perspective","volume":"77","author":"Scialla JJ","year":"2021","unstructured":"Scialla JJ, Kendrick J, Uribarri J, Kovesdy CP, Guti\u00e9rrez OM, Jimenez EY, Kramer HJ. State-of-the-art management of hyperphosphatemia in patients with CKD: an NKF-KDOQI controversies perspective. Am J Kidney Dis. 2021, 77:132-41. 10.1053\/j.ajkd.2020.05.025","journal-title":"Am J Kidney Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/94581-safety-and-effectiveness-of-roxadustat-in-dialysis-dependent-patients-with-renal-anemia-a-hospital-based-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:45:48Z","timestamp":1707507948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/94581-safety-and-effectiveness-of-roxadustat-in-dialysis-dependent-patients-with-renal-anemia-a-hospital-based-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,23]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.24427","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,23]]}}}